FDA Panel to Weigh Lifting Research Peptide Ban
SkimNews Take
A pharmacy compounding advisory committee is the venue where 19 research peptides could become broadly available — routing what amounts to a drug-access decision through a channel designed for individualized prescriptions, with telehealth platforms positioned as the chief downstream beneficiaries rather than traditional drug manufacturers.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The FDA's pharmacy compounding advisory committee is scheduled to meet July 23-24 to discuss easing restrictions on seven research peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon.
- The advisory panel currently has only three voting members, six vacancies, and one non-voting member from the pharmaceutical industry — a lopsided structure critics cite as evidence the outcome is predetermined.
- Hims & Hers acquired a US-based peptide facility in 2025 and could capture up to $440 million of a projected $2.2 billion annual telehealth peptide market if restrictions ease, according to Wall Street estimates cited in the article.
- RFK Jr. called the Biden administration's 2023 ban on 19 research peptides "illegal" on The Joe Rogan Experience and said he is a "big fan" of peptides he has personally used; the original ban cited risks including priapism and tumor growth.
- BPC-157, marketed as an injury-recovery "wolverine peptide," has positive animal studies conducted primarily by one Croatian research group, but researcher Dr. Flynn McGuire told Stat and Undark in 2025 that it "should not be used by humans."
- Physicians are overwhelmingly concerned about self-directed peptide use, with a poll cited in the article finding 90% worried, even as compounding pharmacies argue legalization would create a safer alternative to the existing gray market, much of which originates in China.
- Dr. Eric Topol of Scripps Research warned "whatever RFK is pushing for will somehow get done," pointing to Kennedy's June 2025 firing of all 17 members of a federal vaccine advisory committee and their replacement with ideological allies as precedent.
Why it matters: Lifting the ban wouldn't mean FDA approval — just legalization of compounding — so millions of Americans could self-inject drugs with minimal human safety data while telehealth platforms like Hims & Hers stand to capture up to $440 million. With 90% of physicians worried and a committee stacked with 6 vacancies, critics see Kennedy's vaccine advisory purge as the template for how this vote will go.
